Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
October 07, 2015 16:15 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Oct. 07, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...
Aegerion Pharmaceuticals Observes Familial Hypercholesterolemia Awareness Day
September 24, 2015 09:25 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Sept. 24, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to...
Aegerion Pharmaceuticals Announces Presentation at the Leerink Rare Disease Roundtable
September 23, 2015 16:15 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Sept. 23, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...
Donald K. Stern, Esq. Appointed to Aegerion Pharmaceuticals' Board of Directors
September 18, 2015 07:50 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Sept. 18, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
September 14, 2015 17:00 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Sept. 14, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
August 12, 2015 08:30 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Aug. 12, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
Aegerion Pharmaceuticals Announces Second Quarter 2015 Financial Results
August 05, 2015 16:10 ET
|
Aegerion Pharmaceuticals, Inc.
- Company records $64.2 million in total net product sales -
- JUXTAPID® net product sales were $57.1 million in the second quarter of 2015, 96% from prescriptions written in the U.S. -
-...
Aegerion Pharmaceuticals Announces Leadership Changes to Support the Next Stage of Growth
July 27, 2015 08:00 ET
|
Aegerion Pharmaceuticals, Inc.
Company Reports Preliminary Second Quarter 2015 Total Net Product Sales of Between $63 and $64 Million and Preliminary Cash and Cash Equivalents of Approximately $82 Million as of June 30,...
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
July 13, 2015 16:10 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., July 13, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
Aegerion Pharmaceuticals Appoints Gregory Perry as Chief Financial Officer
June 25, 2015 07:30 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., June 25, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...